femoxetine

Femoxetine is a **small molecule antidepressant** and **selective serotonin reuptake inhibitor (SSRI)** developed by Novo Nordisk. It acts by inhibiting the serotonin transporter (SERT), thereby increasing synaptic serotonin levels in the central nervous system. Femoxetine was evaluated for the treatment of **major depressive disorder**, obesity, alcoholism, and eating disorders. Clinical studies demonstrated antidepressant efficacy comparable to tricyclics (e.g., amitriptyline, imipramine), with fewer anticholinergic side effects, and explored potential benefit in obese patients. However, the drug was discontinued and is not marketed in any country[2][4][5][6][8][12].

Brand names

Malexil

Other names

femoxitine